Sign in
CompletedPhase 3

Phase 3 Study of Plozasiran in Adults With Hypertriglyceridemia

Key facts

Who runs it
Arrowhead Pharmaceuticals
Where
Annapolis, Asheboro, Baltimore, Beavercreek, Beverly Hills, Birmingham, Bountiful, Canoga Park, Chattanooga, Cincinnati, Clearwater, Colorado Springs, Columbus, El Paso, Elkhart, Flint, Fort Mill, Fort Worth, Garden Grove, Greenville, Hialeah, Horsham, Houston, Huntington Beach, Indianapolis, Jefferson City, Lake City, Lake Forest, Laredo, Las Vegas, Lawrenceville, Lincoln, Long Beach, Louisville, Macon, Manassas, Miami Lakes, Minneapolis, Missouri City, Mobile, Montclair, Morehead City, Mt. Dora, New York, Newport, Norfolk, Norman, North Miami Beach, Oklahoma City, Olive Branch, Omaha, Orlando, Overland Park, Oxnard, Park Ridge, Pensacola, Philadelphia, Plano, Powell, Redding, Riverhead, Rochester, San Antonio, Sarasota, Savannah, Seattle, South Bend, St Louis, St. George, Sugar Hill, Sugar Land, Summit, Tamarac, The Bronx, Tomball, Topeka, Van Nuys, Vestal, Victoria, Wilkes-Barre, Wilmington, Winston-Salem, and Zachary, United StatesSee the 97 sitesAlso in 14 other countries, 138 sites
Status
Completed
Phase
Phase 3
People taking part
1,456 people enrolled
Started
21 May 2024
Ended
8 Sept 2026
Type of study
Interventional, 2 groupsOne group gets a placebo (a dummy treatment), for comparison.
Treatments tested
  • Plozasiran Injection
  • Placebo
Record updated
25 September 2026

Who can take part

Age
18 years and older
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 11 criteriaShow less

Who can take part

  • Males, or nonpregnant (who do not plan to become pregnant) nonlactating females, who are ≥18 years of age at screening
  • Established diagnosis of hypertriglyceridemia (HTG) and prior documented evidence (medical history) of mean fasting TG level ≥150 mg/dL (≥1.69 mm/L) and ≤499 mg/dL (≤5.64 mmol/L)
  • Mean fasting TG level ≥150 mg/dL (≥1.69 mmol/L) and ≤499 mg/dL (≤5.64 mmol/L) collected at 2 separate and consecutive visits at least 7 days apart and no more than 17 days apart during the screening period
  • Fasting low density lipoprotein-cholesterol (LDL-C) ≤ 130 mg/dL (≤3.37 mmol/L) at screening
  • Screening HbA1c ≤9.0%
  • Willing to follow diet counseling and maintain a stable low-fat diet
  • Must be on standard of care lipid and TG-lowering medications per local guidelines (unless documented as intolerant as determined by the Investigator, including an inability to safely administer or re-administer a specific drug because of fear, preference, genetic, clinical, or metabolic considerations, or due a previous adverse reaction associated with, attributed to, or caused by specific drug) prior to collection of qualifying TG levels

Who cannot take part

  • Use of any hepatocyte-targeted small interfering ribonucleic acid (siRNA) that targets lipids and/or triglycerides within 365 days before Day 1 (except inclisiran, which is permitted). Administration of investigational drug and inclisiran must be separated by at least 4 weeks
  • Acute pancreatitis within 4 weeks prior to screening
  • Use of any other hepatocyte targeted siRNA or antisense Oligonucleotide molecule within 60 days or within 5-half-lives before Day 1 based on plasma pharmacokinetics (PK), whichever is longer
  • Body mass index >45 kg/m\^2; Note: Additional Inclusion/Exclusion criteria may apply per protocol

Where in United States

Also in 14 other countries, 138 sites

  • Annapolis, MarylandHospital not named in the registry
  • Asheboro, North CarolinaHospital not named in the registry
  • Baltimore, MarylandHospital not named in the registry
  • Beavercreek, OhioHospital not named in the registry
  • Beverly Hills, CaliforniaHospital not named in the registry
  • Birmingham, AlabamaHospital not named in the registry
  • Bountiful, UtahHospital not named in the registry
  • Canoga Park, CaliforniaHospital not named in the registry
  • Chattanooga, TennesseeHospital not named in the registry
  • Cincinnati, OhioHospital not named in the registry
  • Clearwater, FloridaHospital not named in the registry
  • Colorado Springs, ColoradoHospital not named in the registry
  • Columbus, OhioHospital not named in the registry
  • Columbus, OhioHospital not named in the registry
  • El Paso, TexasHospital not named in the registry
  • Elkhart, IndianaHospital not named in the registry
  • Flint, MichiganHospital not named in the registry
  • Fort Mill, South CarolinaHospital not named in the registry
  • Fort Worth, TexasHospital not named in the registry
  • Garden Grove, CaliforniaHospital not named in the registry
  • Greenville, South CarolinaHospital not named in the registry
  • Hialeah, FloridaHospital not named in the registry
  • Horsham, PennsylvaniaHospital not named in the registry
  • Houston, TexasHospital not named in the registry
  • Houston, TexasHospital not named in the registry
  • Houston, TexasHospital not named in the registry
  • Houston, TexasHospital not named in the registry
  • Houston, TexasHospital not named in the registry
  • Houston, TexasHospital not named in the registry
  • Houston, TexasHospital not named in the registry
  • Houston, TexasHospital not named in the registry
  • Houston, TexasHospital not named in the registry
  • Huntington Beach, CaliforniaHospital not named in the registry
  • Indianapolis, IndianaHospital not named in the registry
  • Jefferson City, MissouriHospital not named in the registry
  • Lake City, FloridaHospital not named in the registry
  • Lake Forest, CaliforniaHospital not named in the registry
  • Laredo, TexasHospital not named in the registry
  • Las Vegas, NevadaHospital not named in the registry
  • Lawrenceville, GeorgiaHospital not named in the registry
  • Lincoln, CaliforniaHospital not named in the registry
  • Long Beach, CaliforniaHospital not named in the registry
  • Louisville, KentuckyHospital not named in the registry
  • Macon, GeorgiaHospital not named in the registry
  • Manassas, VirginiaHospital not named in the registry
  • Miami Lakes, FloridaHospital not named in the registry
  • Minneapolis, MinnesotaHospital not named in the registry
  • Missouri City, TexasHospital not named in the registry
  • Mobile, AlabamaHospital not named in the registry
  • Montclair, CaliforniaHospital not named in the registry
  • Morehead City, North CarolinaHospital not named in the registry
  • Mt. Dora, FloridaHospital not named in the registry
  • New YorkHospital not named in the registry
  • New YorkHospital not named in the registry
  • Newport, PennsylvaniaHospital not named in the registry
  • Newport, PennsylvaniaHospital not named in the registry
  • Norfolk, NebraskaHospital not named in the registry
  • Norman, OklahomaHospital not named in the registry
  • North Miami Beach, FloridaHospital not named in the registry
  • Oklahoma City, OklahomaHospital not named in the registry
  • Oklahoma City, OklahomaHospital not named in the registry
  • Olive Branch, MississippiHospital not named in the registry
  • Omaha, NebraskaHospital not named in the registry
  • Omaha, NebraskaHospital not named in the registry
  • Orlando, FloridaHospital not named in the registry
  • Overland Park, KansasHospital not named in the registry
  • Oxnard, CaliforniaHospital not named in the registry
  • Park Ridge, IllinoisHospital not named in the registry
  • Pensacola, FloridaHospital not named in the registry
  • Philadelphia, PennsylvaniaHospital not named in the registry
  • Plano, TexasHospital not named in the registry
  • Powell, TennesseeHospital not named in the registry
  • Redding, CaliforniaHospital not named in the registry
  • Riverhead, New YorkHospital not named in the registry
  • Rochester, New YorkHospital not named in the registry
  • San Antonio, TexasHospital not named in the registry
  • Sarasota, FloridaHospital not named in the registry
  • Savannah, GeorgiaHospital not named in the registry
  • Seattle, WashingtonHospital not named in the registry
  • South Bend, IndianaHospital not named in the registry
  • St Louis, MissouriHospital not named in the registry
  • St. George, UtahHospital not named in the registry
  • Sugar Hill, GeorgiaHospital not named in the registry
  • Sugar Land, TexasHospital not named in the registry
  • Summit, New JerseyHospital not named in the registry
  • Tamarac, FloridaHospital not named in the registry
  • The Bronx, New YorkHospital not named in the registry
  • The Bronx, New YorkHospital not named in the registry
  • Tomball, TexasHospital not named in the registry
  • Topeka, KansasHospital not named in the registry
  • Van Nuys, CaliforniaHospital not named in the registry
  • Vestal, New YorkHospital not named in the registry
  • Victoria, TexasHospital not named in the registry
  • Wilkes-Barre, PennsylvaniaHospital not named in the registry
  • Wilmington, North CarolinaHospital not named in the registry
  • Winston-Salem, North CarolinaHospital not named in the registry
  • Zachary, LouisianaHospital not named in the registry

About the trial

What the trial wants to find out

This Phase 3 study will evaluate the safety and efficacy of plozasiran injection (ARO-APOC3) in adult participants with hypertriglyceridemia (HTG). After providing informed consent eligible participants will be randomized to receive 4 doses (once every 3 months) of plozasiran or placebo and be evaluated for efficacy and safety.

The 2 groups in the trial

  • Plozasiran InjectionTreatment being tested

    4 doses of plozasiran by subcutaneous (sc) injection

  • PlaceboPlacebo, for comparison

    calculated volume to match active treatment by sc injection

Data and sources

Registry record
Listed on ClinicalTrials.gov and on the EU's official list of trials (CTIS).How to verify a trial in the registry
Official title
Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Plozasiran in Adults With Hypertriglyceridemia
Record updated
25 September 2026